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Abstract 
 
Breast Cancer lethality is mostly due to metastization, an event that involves cells 
migration and invasion, with the latter being dependent of extracellular matrix  degradation. 
Due to metalloproteinases (MMPs) role in migration and invasion and correlation of up-
regulation of MMP-2 and 9 (gelatinases) with tumor aggressiveness, these enzymes are 
considered important druggable targets. 3D models, namely spheroids, have been described 
as more physiological relevant models. Therefore this work aimed to i) implement breast 
cancer spheroids model for migration studies; and ii) to evaluate the potential of two pyridine-
containing macrocyclic compounds [15]pyN5 and [16]pyN5 as MMP inhibitors. The MMP-2 
inhibitor ARP-100 was used as control. Spheroids of MDA-MB-231 cells were developed using 
MatrigelTM in non-adherent culture plates, being monolayer cultures used as controls. During 
the whole culture time, compact spheroids with diameters of ~200 μm were obtained, 
containing evenly distributed cells, with different gelatinase secretion when compared to 
monolayer cultures. The cytotoxicity of the compounds (1-100 µM) was evaluated, through a 
24 h tetrazolium-based assay. Cell viability was > 70%  for concentrations up to 50 µM of all 
compounds, in 2D and 3D cultures. The effect of these compounds (1-40 µM) on gelatinases 
activity was evaluated by a modified zymography technique. For 3D conditioned media both 
[15]pyN5 and [16]pyN5 at 7.5 µM revealed a 100% inhibition of MMP-2/9, while ARP inhibited 
52% and 84% of MMP-9 and MMP-2 activity, respectively. Cell migration was analyzed 
through radial migration and scratch assay for 3D and 2D cultures, respectively. Migration in 
2D models was affected (p<0.05) by both pyridine-containing macrocycles (5 μM), but not 
significantly by ARP-100 (up to 40 μM). Radial Migration was less extensively affected, having 
only significant inhibition for [16]pyN5 (20 μM) and ARP-100 (40 μM). In the future, invasion 
assays will be performed to further explore the therapeutic potential of these promising 
pyridine-containing macrocycles.  
 
Key-Words: 3D models, breast cancer, cell migration, gelatinases, MMPs Inhibitors  
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Resumo 
 
O cancro de mama foi, em 2012, a 5ª causa de morte por cancro no mundo [1]. A 
maioria destas mortes deve-se à metastização, facto que se reflete na taxa de sobrevida a 5 
anos que em cancros localizados é de 98,6% enquanto em cancro disseminado de mama é 
de 25,9% [2]. A metastização envolve migração e invasão celular, capacidades que as células 
tumorais de mama adquirem através da transição epitelial-mesenquimal. Esta transição 
consiste numa mudança de célula epitelial para uma célula do tipo mesenquimatosa e é 
caracterizada pela perda dos marcadores epiteliais, nomeadamente proteínas de interação 
célula-célula, célula-matriz extracelular (ECM), proteínas do citoesqueleto e perda de 
polarização. Simultaneamente, as células ganham a plasticidade necessária para a 
migração/invasão [3]. Este processo depende de proteases, entre as quais as 
metaloproteases de matriz (MMPs), grupo de enzimas dependentes de zinco que clivam 
elementos da matriz extracelular, entre outras funções [4]. As MMPs, especialmente o grupo 
das gelatinases (MMP-2 e 9), têm sido bastante associadas a tumores metastáticos e estão 
correlacionadas com a agressividade de alguns tumores [5]. Dado que as MMPs foram 
identificadas como possíveis alvos terapêuticos, foram desenvolvidos inibidores destas 
enzimas. Estes inibidores demonstraram resultados pré-clínicos promissores, mas já em fase 
clínica mostraram falta de eficácia e efeitos secundários de síndrome musculosquelético. 
Uma das hipóteses sugerida para este insucesso responsabilizava o grupo quelante de zinco 
comum a muitos destes inibidores, o ácido hidroxâmico [6]. No nosso laboratório foram 
sintetizados dois macrociclos do tipo pentaaza contendo um grupo piridina no anel, o [15]pyN5 
e o [16]pyN5. Estes compostos têm a particularidade de apresentarem constantes de 
estabilidade elevadas para o catião Zn(II), tendo sido avaliado o seu potencial como inibidores 
de MMPs e consequentemente da migração celular. 
Por outro lado a elevada taxa de insucesso no desenvolvimento de fármacos na área 
de oncologia, revela a necessidade de ter modelos in vitro mais preditivos [7]. Os modelos 
celulares 3D vêm assim fazer uma ponte entre os modelos animais, mais complexos, e os 
modelos celulares 2D. Os modelos 3D são fisiologicamente mais relevantes do que os 
modelos de monocamada por simularem melhor as interações célula-célula, e na presença 
de ECM, as interações célula-matriz. Estes modelos são especialmente úteis no estudo de 
cancro dada a importância do microambiente tumoral para a progressão tumoral, incluindo a 
metastização [8]. Dos vários modelos 3D, os esferoides têm sido dos mais estudados. Estes 
modelos também são capazes de criar o gradiente de nutrientes e oxigénio que ocorre 
naturalmente in vivo, gradientes importantes para criar uma heterogeneidade de células 
proliferativas e por vezes até de centros necróticos [9].  
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Assim sendo, os objetivos deste trabalho foram utilizar a linha celular metastática de 
adenocarcinoma mamário, MDA-MB-231 para desenvolver modelos 3D. O modelo clássico 
2D, foi utilizado como controlo. Nestes modelos testaram-se os compostos [15]pyN5 e 
[16]pyN5 como inibidores das MMPs, especificamente das gelatinases, e estudou-se o seu 
efeito na migração celular, comparativamente com um inibidor comercial da MMP-2, o ARP-
100.  
O primeiro passo consistiu em implementar e optimizar os modelos 3D, utilizando 
placas de baixa aderência para a formação de agregados celulares. Por representar o melhor 
consenso entre esferoides morfologicamente homogéneos e razão célula/meio que 
permitisse o condicionamento de meio, escolheu-se um inóculo de 250.000 células/mL, 
obtendo-se esferoides com uma média de diâmetros de 200 μm. A caracterização de cortes 
histológicos dos esferoides do dia 4 de cultura, por hematoxilina & eosina, revelaram 
distribuição homogénea de células, a presença de ECM e ausência de centros necróticos. No 
entanto, a quantificação de proteína total, o ensaio de viabilidade por MTS e a 
imunomarcação com Ki-67 revelaram reduzida proliferação. O condicionamento de meio de 
culturas 2D e de esferóides e subsequente análise dos dois revelaram que os esferóides 
exibiam maior atividade da MMP-9 do que a MMP-2, contrariamente ao observado nas células 
em monocamada.  
A citotoxicidade dos compostos (1-100 µM) foi avaliada em ensaios de 24 horas com 
MTS, ensaio baseado na bioredução de um tetrazólio, de forma a selecionar as 
concentrações a serem usadas nos ensaios seguintes. A viabilidade para ambos os 
macrociclos contendo piridina revelou-se semelhante nos modelos 3D e nos 2D, não sendo 
inferior a 70% até 50 µM. Já para o ARP-100, a viabilidade celular no modelo 2D revelou-se 
mais baixa do que no modelo 3D, com concentrações acima de 50 µM.  
Seguidamente, o ensaio de zimografia de gelatina para análise da atividade das 
gelatinases foi implementado e otimizou-se o condicionamento de meio para a sua análise. A 
utilização de EDTA confirmou a natureza metalo-proteica das bandas observadas. Havendo 
a hipótese dos compostos se libertarem das gelatinases durante a eletroforese, fenómeno 
que ocorre com os inibidores endógenos das MMPs, modificou-se o ensaio de zimografia. A 
modificação consistiu em colocar os compostos ([15]pyN5 [16]pyN5 e ARP-100) em contacto 
com as gelatinases já após a eletroforese, na fase de degradação gelatinolítica. Desta forma 
garantiu-se que as diferenças observadas nas bandas resultavam do efeito direto dos 
compostos.  
O teste dos compostos demonstrou que o ARP-100 a 40 μM resultou numa inibição 
de 100%. No que respeita aos macrociclos, estes não inibiram a actividade gelatinolítica de 
meio condicionado das culturas 3D a 5 μM, mas atingiram notavelmente, 100% de inibição a 
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7,5 μM. Esta curva dose-resposta correlaciona com o zinco livre em condições fisiológicas, 
para ambos os compostos.  
O efeito dos compostos na migração celular em 2D foi testado com ensaios de ferida. 
Este ensaio consiste em fazer um risco numa monocamada confluente e medir a distância 
entre os extremos da ferida ao tempo 0, e neste caso, às 24 horas, o que indica a migração 
celular. Para os esferóides, fizeram-se ensaios de migração radial, colocando os esferóides 
sobre um revestimento de MatrigelTM, onde estes aderem. Após 24 horas mediram-se as 
distâncias entre as células migradas e a superfície dos esferóides. A migração no modelo 2D 
foi afetada com os compostos macrocíclicos contendo piridina a 5 μM: [16]pyN5 reduziu 
38±2% e [15]pyN5 reduziu 21±4% da migração. No entanto, o efeito de inibição destes 
compostos não aumentou com a concentração. O ARP-100 pelo contrário, não demonstrou 
efeitos significativos de inibição até 40 μM. A migração dos modelos 3D revelou-se assim 
menos afectada pelos compostos. Os compostos macrocíclicos contendo piridina só 
demonstraram redução da migração aos 20 e 40 μM, só sendo significativa para o [16]pyN5 
a 20 μM (20±4%). O ARP-100 apenas diminuiu 23±3% da migração celular a 40 μM (p<0.05).  
Concluindo, os modelos 3D de cancro de mama para o estudo de processos 
envolvidos na metastização, foram implementados e caracterizados com sucesso. Estes 
modelos demonstraram diferenças relativamente às células em monocamada. Aqui, 
reportámos também, que os dois compostos [15]pyN5 e [16]pyN5  reduziram a migração em 
monocamada e, de uma forma mais ligeira, a migração celular nos modelos 3D. Este efeito 
na migração envolve a inibição da atividade gelatinolítica da MMP-2 e MMP-9, e 
possivelmente das outras MMPs. Os dois macrociclos contendo piridina aparentaram ser 
mais potentes nestas funções relativamente ao ARP-100. 
Como perspetiva futura, pretende-se testar o [15]pyN5, o [16]pyN5  e o ARP-100 na 
invasão celular, dado o papel das MMPs ser ainda mais relevante neste processo. Também 
pretendemos investigar o mecanismo de inibição das MMPs com [15]pyN5 e [16]pyN5 através 
de estudos in silico. 
 
Palavras-chave: modelos 3D, cancro de mama, migração celular, gelatinases, inibidores de 
MMPs 
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1.Introduction  
 
1.1. Breast Cancer 
Although much progress has been achieved in breast cancer treatment, efforts applied 
in cancer research should not diminish. In 2012, breast cancer was the 2nd most diagnosed 
cancer and the 5th leading cause of dead by cancer worldwide [1], and its incidence is 
continuously increasing by the dissemination of developed countries risk factors such as 
aging, overweight, tobacco and alcohol consumption and also hormone treatments and 
reproductive trends [10]. The improvement made in detection methods allows for earlier 
diagnosis, preventing tumors progression into more aggressive stages and its metastization, 
explaining the decrease of breast cancer lethality in developed countries. Adjuvant therapy 
has also aided in decreasing lethality, but therapies targeting specifically tumor cells migration 
and invasion steps are still of great demand. In breast cancer, the occurrence of distant 
metastasis is particularly relevant, as nearly all breast cancer–related deaths are not caused 
by the primary tumor [10, 11]. 
 
1.2. Tumor Cells Migration and Invasiveness and the Role of Tumor 
Microenvironment 
A crucial step for processes such as embryonic morphogenesis and wound healing is 
the Epithelial to Mesenchymal Transition (EMT), in which cells gain the ability to migrate. It 
has been found that tumor cells can also advantageously use EMT, allowing them not to be 
confined to a specific tissue, thus metastasizing to other sites. EMT comprehends the loss of 
epithelial markers such as tight and adherent junction proteins, e.g. E-cadherin, desmoplakin, 
occludins and claudins, and intermediate filaments, e.g. cytokeratin-8, 9 and 18, resulting in 
loss of basal-apical polarity. Alongside, these cells also gain mesenchymal markers N-
cadherin, cytokeratin -5 and 14, vimentin, smooth muscle actin and myosin. Some of them are 
also markers of basal/myoepithelial breast cells. With the acquired plasticity, tumor cells 
develop protrusions in their leading edge, through actin filaments polymerization, and then 
form focal contacts by integrin binding extracellular matrix (ECM) proteins. ECM Proteases, 
such as matrix metalloproteinases (MMPs), are recruited to the leading edge for localized 
proteolysis of ECM net, clearing away for cell movement which unfolds by myosin-mediated 
actin filament contraction and simultaneously detachment of the trailing edge by focal contact 
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disassembly. Cells may migrate individually or collectively, depending on the state of cell-cell 
adhesions (e.g. cadherins and gap junctions) [reviewed in [3, 12] . 
The loss of E-cadherin, which compromises cell-cell-aggregation, is one of the most 
important events in EMT, such that simply silencing E-cadherin induces this process.  
Nevertheless, the role of E-cadherin cannot be reduced to a structural function as full EMT 
was not observed in E-cadherin mutants lacking only its ectodomain [13]. In vivo, E-cadherin 
loss can be due to mutations in its promoter or downregulation by transcriptional factors such 
as Slug, Twist and SnaiI [14]. During the E-cadherin depletion, β-catenin, which is sequestered 
in its cytoplasmic domain, is released. If β-catenin is unphosphorylated, it can activate the 
expression of EMT-inducing transcriptional factors [13]. GSK3β (Glycogen synthase kinase -
3β), the protein responsible for the phosphorylation of β-catenin, has its activity inhibited by 
hypoxia. In fact, it is long established the importance of hypoxia for tumor progression for its 
role as an inducer of several EMT-transcriptional factors (e.g. Hypoxia-inducible factor 1-α, 
SnaiI and Twist1). Moreover, hypoxia also increases chemotherapeutics resistance [14, 15]. 
ECM has a major role in mesenchymal migration, not only as a barrier, but also as 
substrate [3]. Besides its structural function, ECM has been shown to have essential roles in 
normal and malignant breast tissue development by inducing specific signaling pathways. 
Indeed, the ECM undergoes structural and composition changes during tumor development, 
particularly in breast tumor, ECM gains a characteristic stiffness. Levental et al. [16] showed 
that this stiffness can be caused by lysyl oxidase (LOX)-induced collagen crosslinking. This 
event induces tension-dependent integrin clustering and consequently promotes focal 
adhesions which increase growth and invasion of premalignant epithelium through 
Phosphoinositide 3-kinase (PI3K). This increased malignancy was not observed with the 
inhibition of Lox, PI3K or clusterisation of integrins. Among LOX regulators are transforming 
growth factor-β (TGF-β) [16] and hypoxia [17]. 
These examples are just a glimpse of the complex influence that tumor 
microenvironment has in tumor development. It is also noteworthy that much remains to be 
clarified about EMT, as there are doubts about its relevance in vivo, for not all circulating tumor 
cells exhibit a mesenchymal phenotype. But again as stated by Li et al. [18], EMT “is not a 
binary process, but instead includes a spectrum of intermediate states that have different 
degrees of simultaneous expression of epithelial and mesenchymal markers,” and which is 
probably regulated by redundant pathways. Also, it has been reported a cancer cell line 
performing “amoeboid” migration, a proteolytic-independent migration, characterized by very 
few focal contacts cell-matrix [19], which role in vivo is still unknown.  
 
3 
 
 
1.3. MMPs 
As aforementioned, MMPs also have an important role in tumor metastization. In fact, 
some of these proteinases correlate with increased tumor aggressiveness in  primary breast 
cancer cells and cell lines [5, 20, 21], suggesting a potential role as biomarkers. Furthermore, 
MMPs have been connected with diseases in the nervous, cardiovascular and respiratory 
systems, and disorders of the immune system, such as the abnormal tissue proteolysis typical 
of arthritis [6, 21]. Moreover, MMPs also participate in matrix-cell signal transduction 
modulation as during ECM degradation, peptides with chemotactic functions are generated, 
further inducing tumor migration [3, 22]. Also some growth factors, such as fibroblast growth 
factors (FGF) and vascular endothelial growth factors (VEGF), which are sequestered by the 
ECM protein, heparin, are released, inducing tumor proliferation, angiogenesis and/or 
migration [24, 25]. Some of MMPs’ roles in regulation of tumor microenvironment, including 
migration/invasion, are depicted in Fig. 1 [26]. 
 
Figure 1.  MMPs’ regulation of Tumor Microenvironment (EBM-endothelial basement 
membrane; BM-bone marrow) [26]. 
MMP constitutes a family of 24 zinc (Zn2+) dependent endopeptidases, which are 
currently grouped by their ECM substrate and domain organization: collagenases (MMP-1, 8 
and 13); gelatinases (MMP-2 and 9); stromelysin (MMP-3, 10 and 11); matrylisins (MMP-7 
and 26); membrane type MMPs (MT-MMPs), etc. Despite this nomenclature, it has been 
shown that MMPs have a substantial substrate overlap and can virtually cleave any ECM 
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component and in some cases growth factors, cell adhesion molecules and other proteases 
precursors as well [23, 27]. 
MMPs catalytic domain is quite conserved, containing a catalytic Zn2+ ion (Fig. 2 [22]). 
They also contain a structural  Zn2+ ion and one to three Ca2+ ions [28]. The catalytic Zn2+ ion 
is coordinated by three histidine residues contained in the conserved motif HExGHxxGxxH 
and a fixed water molecule, which is simultaneously hydrogen bonded to the protonated 
carboxyl group of the catalytic glutamic acid residue [29]. The cleavage of the peptide bond, 
as illustrated in Fig. 2, is mediated by the zinc ion, water molecule and a nearby residue which 
functions as an hydrogen donor [30]. This catalytic site is flanked by three pockets on the right 
and left side [31].  
 
 
Figure 2. MMP catalytic center with a modeled Pro-Leu-Gly-Leu-Ala-Gly-amide hexapeptide 
substrate [22]. 
 
Another common structure to MMPs is the hemopexin-like C-terminal domain which is 
essential for non-proteolytic functions of MMPs [26]. Finally, most MMPs also have a highly 
conserved signal peptide for secretion, and are produced as zymogens, requiring a pro-
peptide cleavage for activation, which depending on the MMP can occur intracellularly or 
extracellularly, and can include different proteins for its activation [20, 23]. This pro-peptide 
domain contains a conserved “cysteine switch” motif at the N-terminal, in which the sulfhydryl 
group of the cysteine residue integrates in a tetrahedral coordination sphere with the Zn2+ ion, 
blocking its activity and maintaining enzyme latency [31]. 
MMP activity is not directly correlated to its expression/secretion as they have 
endogenous inhibitors, the tissue inhibitors of matrix metalloproteinase (TIMPs). Four TIMPs 
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have been described in humans with different localization and substrate specificity. Besides 
this specificity, they still have a considerable substrate overlapping. TIMPS are homologous 
proteins highly conserved in their immediate N-terminal region through which interacts with 
the MMPs catalytic domain. A key event in this inhibition is the bidentate coordination of the 
Zn2+ by N-terminal cysteine residue of TIMPs, which displaces the water molecule coordinated 
by Zn2+ from the enzyme [32]. However, because TIMPs can target other proteins than MMPs, 
their effects are not restricted to the ones directly related to MMP inhibition, having either pro 
or anti-proliferative, and even anti-apoptotic effects which makes their role in cancer 
ambiguous. In fact, TIMP-1 correlates with lung metastasis and breast cancer stage [21, 33]. 
As neither the expression of TIMPs can be completely correlated to MMP activity, nor their 
effects are solely anti-tumorigenic, they are not greatly considered as a possible therapy 
target. 
Similarly, although initially was thought all MMPs had a detrimental effect on cancer, 
the opposite was shown, with some MMPs presenting beneficial roles in cancer [6]. Hence, 
targeting MMPs’ for therapy should be carefully addressed as further studies on their functions 
should be made.  
 
Gelatinases (MMP-2 and 9) 
 
MMP-2 and MMP-9, gelatinases A and B, respectively, are some of MMPs that have 
a higher correlation with metastatic cancer and are indicative of worse prognosis [34, 35]. 
MMP-9 correlation with the stage of cancer is particularly strong, being shown in one 
epidemiological study that the concentration of this protein decreased after surgical removal 
of the tumor. This concentration remained low increasing again only 1 to 8 months before 
diagnosis of recurrence for 20% of patients. It even correlated to the cases in which there was 
a lack of response to therapy [36]. However, in tumor microenvironment, not just tumor cells 
are responsible for MMP-2/9 production. Breast cancer cells MDA-MB-231 were able to 
release MMP-2 bound to non-malignant fibroblasts membrane [37] and it was shown that 
neutrophils synthesis and secretion of MMP-9, has an important role in tumor progression [38]. 
Although MMPs are highly homologous proteins, gelatinases have a unique domain, 
the fibronectin type II repeats (Fig. 3 [23]), which aids in the binding to fibronectin, gelatin or 
collagen for their cleavage. Selectivity has been a major focus in terms of MMP inhibitors 
design. In this sense, a big emphasis to the S1’ pocket was given as it was the one differing 
the most among MMPs.  This pocket is hydrophobic, more in MMP-2 than 9, and is open with 
no significant interactions. The major difference between MMP-9 and 2 is a loop present in 
the former and not in the last [29].  
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Figure 3. Gelatinases basic domain structure [23]. Common to MMPs: Pre-peptide signal, Pro-
propetide domain; Zn- highly conserved zinc-binding site; H- Hinge region linking the Hemopexin-like 
domain to the catalytic domain (not existing in MMP-2); Specific for gelatinases: II-fibronectin type II 
repeats.  
MMP-2 pro-form of 72 kDa can be proteolytically activated to a 66 kDa form, by MMP-
1, 7, thrombin and TIMP-2. TIMP-2 interacts through its C-terminal with MMP-2 hemopexin 
domain and through its N-terminal with MT-MMP1 (MMP-14). The MMP-2 pro-domain is then 
cleaved when a second MT-MMP-1 joins the complex and interacts with the first MT-MMP1 
hemopexin domain. Although TIMP-3 and TIMP-4 can also form these complexes, by not 
allowing cleavage of pro-MMP-2, they act as inhibitors of the complex. The activated MMP-2 
in its turn can activate other MMPs such as MMP-9, MMP-1 and MMP-13 [27, 39, 40]. 
Moreover, the 92 kDa pro-MMP-9 can be activated to a 83 kDa form by plasmin, trypsin 2, 
MMP-3 and MMP-13 [23, 40].  
The MMP-9 is also the only MMP known to form homodimers, by their hemopexin 
domains binding. These homodimers have been associated to CD44 complex, which is 
thought to protect MMP-9 from inhibition by TIMP-1 and to have a role in migration/invasion 
perhaps more relevant than MMP-9 monomers [41]. 
Despite their name, gelatinases also cleave other ECM proteins, such as collagen type 
IV, V, VII, IX and X [23]. The gelatinase substrates also include molecules with signaling 
functions. For example, gelatinases were shown to activate TGF-β by proteolytic activation of 
pro-TGF-β, and also by releasing it from latent TGF-β-binding protein 1 (LTBP1), an ECM 
protein [42][43]. Although TGF-β has dual roles in cancer, some cancer cells gain mutations 
that turn them insensitive to TGF-β tumor suppressive arm, but keep TGF-β  pro-tumor 
functions involved in EMT, tumor growth, etc. [44]. In a similar manner, TIMP-free MMP- 9 
releases VEGF and FGF-2 bound to the ECM [38, 45] promoting angiogenesis. MMP-2 
induces VEGF expression, by interacting with integrin αVβ3 that activates PI3K/Protein Kinase 
B (AKT) pathway and transcription factors downstream, such as HIF-1α. VEGF in turn, further 
induces MMP synthesis [46]. Indeed, Nakamura et al. [47] showed that administration of a 
MMP-9 and 2 inhibitor MMPi270, decreased lymph node metastasis and in vitro presented 
inhibition of lymphangiogenesis properties such as invasion and tube formation. For 
migration/invasion specific pathways it was reported that MMP-9 induced expression by 
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Epithelial Growth Factor Receptor (EGFR) caused the loss of E-cadherin [48] which, as herein 
earlier described, is a fundamental step in EMT. Also, during ECM proteolysis, MMP-9  and 
MMP-2 produce  peptides with chemotactic effects, such as the N-terminal ectodomain of 
Ninjurin1 [49] and Laminin 5γ2 fragment [50], respectively. However, it is noteworthy the 
ambiguous role that gelatinases, as other MMPs and TIMPs have. Potent suppressors of 
angiogenesis, angiostatin and a monomeric NC1 domain, result from the degradation of 
plasminogen and collagen IVα3, respectively, by MMP-9 [51, 52]. Tumors with sizes over 500 
mm3, in MMP-9-deficient mice had accelerated growth relative to control, correlating to low 
tumstatin [52]. Moreover, MMP-9 promoted an anti-tumor immune response, including 
massive neutrophils infiltration and significantly induced tumor regression in mice models [53].  
 
1.4. Exogenous MMP Inhibitors (MMPi) 
The role of MMPs in tumor development lead to the creation of several MMP inhibitors. 
The first class of inhibitors consisted of peptidomimetics, compounds which contained 
pseudopeptides that mimic peptidic bonds, inhibiting MMP action by reversible competitive 
inhibition, occupying the substrate site and chelating zinc. Due to the MMP promiscuity, by 
mimicking the collagen MMP’s cleavage site, these compounds have a relatively broad action 
[23, 54].  
Many zinc-binding groups such as aminocarboxylates, sulfhydryls and derivates of phosphoric 
acid have been tested for MMP inhibition [54]. However, by having a stronger binding with 
MMPs, creating hydrogen bonds with residues of Glu and Ala, conserved aminoacids of MMPs 
catalytic site, the hydroxamates derivates were the ones receiving more focus with more of 
these compounds entering clinical trials [55]. Batimastat was the first MMPi entering clinical 
trials but had limitations in its administration route due to solubility issues [56]. The next 
generation of these compounds, such as marimastat, in Fig. 4, were soluble enough to allow 
oral administration [57, 58]. Despite showing very promising pre-clinical data, when used in 
clinical trials marimastat failed to increase overall survival and induced musculoskeletal 
syndrome (MSS) side effect that also characterized treatments based on other MMPi [59]. 
Although specific inhibition of  some MMPs such as MMP-1 was indicated as a possible cause 
for MSS, it was latter disproven [60, 61]. The next generation of inhibitors was developed taken 
into account these proteins whose structures were then resolved by crystallographic methods. 
The aim was to develop more specific compounds that could surpass the first generation 
problems, regarding lack of efficiency and harmful side effects [6, 31]. Being chelating agents, 
MMPi may off-target non-MMP metal-dependent proteinases [61], hampering a full 
understand of their effects. Besides, as within MMPs, gelatinases have been indicated as 
especially important for metastization, molecules more specific for MMP-2 and 9, were 
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developed. CGS27023A (Novartis) was designed containing an arylsulfonyl group adjacent to 
hydroxamate, which increased the affinity for gelatinases S1 pocket, and thus, its specificity. 
Prinomastat (Pfizer) (Fig. 4) was developed following CGS27023A rational, with increased 
specificity as it contained a diphenylether more suitable for “deep pocket” MMPs [62]. Yet, 
both compounds still maintain some of the first generation MMPi MSS side effects and 
therefore, a translation of the pre-clinical success to clinical trials was not observed.  
 
Figure 4. Chemical structure of some hydroxamic acid MMP inhibitors (Marimastat, Prinomastat 
and ARP-100) and of the macrocyclic compounds containing pyridine ([15]pyN5 and [16]pyN5). 
 
Brown et al [63] developed a mechanism-based inhibitor, SB-3CT, with increased 
specificity for gelatinases. Its specificity for MMP-2 may be due to the induction of pro-MMP-
2 like conformation by directly coordinating the catalytic zinc ion to the sulfur atom of the bound 
inhibitor, forming a tetrahedral coordination at the zinc ion [64]. This mechanism-based 
inhibitor was shown to successfully inhibit ethanol induced in vitro invasion of breast cancer 
cell lines [65], liver metastasis and to increase survival in an aggressive mouse model of T-
cell lymphoma [66]. 
 Using as structural model the arylsulfonamide group contained in prinomastat, CGS-
27023A and retrohydroxymate-based ABT-518, Rosselo et al. [67, 68] developed a set of new 
molecules screened for MMPs inhibitory activity. ARP-100 (compound then denominated 
10a), which is illustrated in Fig. 4, showed to be the most promising considering both its 
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potency for MMP-2 inhibition but also selectivity for this MMP over MMP-1, 3 and 7. This 
selectivity was obtained by adding an alkyl substituent at the carbon atom adjacent to the 
hydroxamic acid, which added lipophilic interactions to the S1 region of the active site. 
Consequently, ARP-100 was tested in HT1080 (fibrosarcoma cell line), inhibiting in ~60% of 
invasive cells (observed by formation of protrusions) in MatrigelTM layered plates (50 nM) [67]. 
ARP-100 was also tested as a gelatinase inhibitor in A549 lung cancer cells (50 and 100 µM) 
as a pharmacological control of MMP-2 siRNA [46], and in a co-culture of SKOV3 cell line with 
primary non-tumor fibroblasts (20-100 nM), where it inhibited adhesion and invasion [69].  
Besides these specifically designed compounds, some other old drugs, such as 
biphosphonates [4, 70] and disulfiram [71] revealed MMPi activity. For disulfiram, mechanisms 
such as decreasing the DNA binding activity of AP-1 and NF-κB, that diminish tumor 
invasiveness, have been shown [72].  
Amongst natural compounds, curcumin has shown anti-carcinogenic properties. Such 
properties have been attributed to the  inhibition of  MMP-2 and 9 in MDA-MB-231 cells through 
TIMP-1 and 4 up-regulation, and by inducting apoptosis and p21 expression’s regulation, 
through a p53-dependent pathway [73]. Also neovastat (AE-941), a water soluble extract from 
shark cartilage, was shown to inhibit tumor growth and progression in vivo through several 
mechanisms including MMP-2, 9 and 12 inhibition and VEGF receptor competitive binding. 
Although in some clinical trials neovastat has improved survival (16.3 versus 7.1 months) in 
refractory renal cancer cell patients [74], no difference was observed between neovastat and 
a placebo in incurable breast or colorectal carcinoma [75].   
Moreover, after being discovered that tetracyclines and their semisynthetic analogues 
could inhibit collagenases [76], derivates of these molecules were produced for just this effect. 
Their antimicrobial activity was chemically removed  and these chemically modified 
tetracyclines (CMT) [77] were evaluated for tumor therapy, with CMT-3 (COL-3 or metastat) 
having the highest anti-tumorigenic potential. Besides gelatinases’ activity and expression 
inhibition [78], CMT-3 can induce apoptosis in tumor cells from 2 to 8-fold more cytotoxic than 
doxycycline, both in a caspase dependent and independent pathway and arrest cells at G0/G1 
phase [79, 80]. After showing promising pre-clinical results, by decreased the number of 
metastasis [79] and delaying tumor growth in rat models [81], CMT-3 entered clinical trials. 
Currently, it is in phase III for Kaposi’s sarcoma and in phase I for advanced cancer. No 
musculoskeletal side effects have been reported yet [21] . 
Finally, one of the long lasting problems that has cursed MMPi clinical trials is the 
design of the clinical trials itself [82]. As aforementioned, MMPs influence in increasing 
malignancy is a quite early event in tumor development and thus pre-clinical data in early-
stage tumors was overall successful. As an example, treatment with batimastat in rats, starting 
2 days prior to tumor surgery until 70th day, resulted in 100% survival after the death of all rats 
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in control group [83]; contrasting with the clinical trials which are based on treatment of patients 
with advance staged tumors. 
 
Macrocycles as MMP inhibitors 
Macrocycles have been potentially described as more specific than open chain 
chelators, for its ring rigidity which constrains the type of metal it can coordinate [84]. The 
macrocycle [12]aneN4 (cyclen) has such a specificity for zinc, that coupled to a fluorophore it 
works as zinc sensor to detect apoptosis [85]. Therefore, in order to develop new compounds 
with MMP inhibitory activity, nitrogen-based zinc binding groups, such as macrocycles, have 
been described. Jacobsen et al.  [86] showed that relatively to one of the most common zinc 
binding groups, acetohydroxamic acid (AHA), macrocycles [9]aneN3, [12]aneN4 and [14]aneN4 
have improved MMP-3 inhibition potency by 185, 139 and 19-fold (IC50), respectively. 
Besides, macrocycles were also much more selective than AHA, as they did not inhibit the 
non-heme iron enzyme soybean lipoxygenase. In contrast, coupling macrocycle compound 
cyclam to marimastat showed no advantages [87]. 
In our laboratory, (Chemical Biology and Toxicology, Faculty of Pharmacy, 
Universidade de Lisboa) [88], two pentaaza-macrocycles containing pyridine in their 
backbone, [15]pyN5 and [16]pyN5 (Fig. 4), were synthesized and have shown high stability 
constants for Zn2+. Moreover, [15]pyN5 complexed with Cu2+, has been studied as a 
superoxide mimetic modulating ROS. This activity was shown to be very promising for cancer 
treatment as it protected MCF-10A (non-malignant cell line) from oxiplatin treatment in 
detriment of further inducing death in cancer cell line MCF-7 [89], and to inhibit cell migration 
and invasion when co-administered with doxorubicin [90].  
 
1.5. Three dimensional models in tumor migration/ invasion assays 
With oncology being one of the areas with higher attritions in drug development, one 
should take a critical look on the models mostly used in pre-clinical phases as they may not 
be translating the in vivo situation [7, 91]. 
It has been broadly described microenvironment factors (e.g. ECM, stromal cells and 
gradients of nutrients/ gases) playing crucial roles in tumor development. Therefore, it is 
reasonable that the development of models, which better represent the interaction of these 
elements, are essential to obtain more accurate predictions of in vivo cells behavior. Although 
animal models partly represent this complexity, they are also expensive, time consuming, raise 
ethical issues and do not represent human systems idiosyncrasies. Besides, specifically for 
tumor context, animal models do not contain the natural tumor cells heterogeneity, and the 
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animals are frequently immunodeficient. As for in vitro models, the current gold standard are 
cell culture monolayers, in which cells adhere to plastic surfaces, have no gradients of 
nutrients and oxygen, and have minimal cell-cell interactions. In this context, three dimensional 
(3D) models of tumor cells emerged as a better alternative by making a bridge between in vivo 
and in vitro monolayers models [8, 92]. The most widely studied and characterized 3D model 
are spheroids which consist in compact cell aggregates that recapitulate in vivo cell-adhesion 
profile inducing reduced proliferative rates relative to monolayers [92]. Besides the three-
dimensionality of cell-cell adhesion, spheroids frequently contain ECM elements either by 
tumor cells intrinsic production or by addition reconstituted extracellular matrix such as 
hydrogels derived from natural sources [92]. Among these, cell adhesion molecules β-
integrins and E-cadherin have critical roles in resistance to chemotherapeutics [93, 94] and 
overall, in malignancy. Weaver et al. [95] has shown that a tumor cell line overexpressing  β1-
integrin, had its phenotype reversed to a less-malignant one both in 3D and in vivo models, 
by treatment with anti-β1 integrin antibody.  
Moreover, spheroids mimic the gradient of nutrients and oxygen that occurs in 
avascular tumor nodules. By being able to develop an hypoxic region and even necrotic cores, 
spheroids can give rise to distinct cell populations: proliferating, quiescent and necrotic [96]. 
Heterogeneity is of extremely importance for chemotherapeutics screenings as the quiescent 
population often is the cause of chemoresistance. It has been shown by Mellor et al. [97] that 
tumor spheroids of quiescent cells exhibited more resistance to common chemotherapeutics 
cisplatin, doxorrubicin, 5-fluorouracil and vinblastine than tumor spheroids composed of 
proliferating cells. 
All together these microenvironment factors differentiate cells in spheroids from cells 
in monolayers. Spheroids of human and mouse tumor cell lines demonstrated transcriptomic 
differences in two enzymes involved in mitochondrial metabolism and redox reactions 
enzymes and downregulation of a DNA mismatch repair enzyme (PMS2 gene), enzymes 
associated with acquired resistance to alkylating agents [98]. Transmembrane proteins also 
suffer changes, as spheroids of MDA-MB-231 cells show β1-integrins [99] and CD44 [100] 
upregulated. Moreover breast cancer spheroid models have shown higher expression of 
ALDH1, MMP1 [100] and urokinase (Upa) [94]. For presenting more stemness-related traits 
and proteins associated to metastization, spheroids respond differently than monolayers to 
compounds targeting EMT [101]. Spheroids of non-malignant breast cancer cells which 
develop an acinar morphology also showed MMP-9 important role in the epithelial polarization 
disruption [102], possibly by interfering with laminin 111, a molecule previously shown to be 
essential for normal acinar morphogenesis [103]. This MMP-9 activity was translated to in vivo 
as its silencing in malignant cells T4-2, hampered their tumorigenic ability in mice [102]. 
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Therefore, spheroids are considered very suitable models also for migration/invasion studies 
[94, 104, 105]. 
Although 3D models offer more technical difficulties than 2D, they have in fact been 
fulfilling their potential. Bissel et al. [106, 107] have shown the importance of microenvironment 
factors on normal and malignant breast tissue development, a groundbreaking work that could 
hardly be done without 3D models. Moreover, in spite of their complexity, they are still in vitro 
models and so high-throughput platforms of 3D models have been developed for 
chemotherapeutic compounds screenings [101, 104, 108]. 
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2. Aims and experimental models 
 
The global aim of this work was to develop more physiologically relevant 3D model of 
metastatic breast cancer, to evaluate the effect of potential MMP inhibitors (MMPi) on cell 
migration.  
MDA-MB-231, a triple negative cell line, obtained from a pleural effusion of an breast 
adenocarcinoma was herein used. MDA-MB-231 cells are metastatic, having both migration 
and invasion potential, and detectable MMP-2 and MMP-9 secretion [5]. Although there are a 
variety of methods to create spheroids, herein non-adhesive plates seemed the most suitable. 
In parallel, monolayers were used as controls.  
Following the hypothesis that the MSS side effects and lack of efficiency from the 
earlier MMPi were due to the zinc-binding group, hydroxamic acid, testing alternative zinc-
binding compound was the next step. Therefore, in this work two pyridine-containing 
macrocyclic compounds, [15]pyN5 and [16]pyN5, were suggested as MMP inhibitors. The 
inhibitory activity of these compounds was evaluated by applying a zymography gel technique 
with gelatin substrate. These compounds were compared with the commercially available 
MMP-2 pharmacological inhibitor, ARP-100, which contains the classical zinc-binding group. 
Moreover, [15]pyN5, [16]pyN5 and ARP-100 effect on cell migration was evaluated through a 
radial and scratch migration, for 3D and 2D cultures, respectively.  
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3. Methods 
  
3.1. Chemicals 
A 40 mM stock solution of ARP-100 (Santa Cruz Biotechnology) was prepared in 
DMSO (Sigma-Aldrich®). Working solutions were performed so that in each final solution, the 
DMSO concentration was kept at 0.25% (v/v). Macrocyclic compounds [15]pyN5 and [16]pyN5 
were dissolved in water at a concentration of 2 mM.  
 
3.2. Maintenance of MDA-MB-231 cells in monolayer cultures 
MDA-MB-231 cells, a human breast carcinoma cell line (ATCC), were inoculated at 
cell densities ranging from 30,000-150,000 cells/ml and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Sigma-Aldrich®) supplemented with 10% fetal bovine serum (FBS) 
(Gibco®, ThermoFisher Scientific). Cultures were kept at 37 °C, under a humidified 
atmosphere at 37 °C, 5% CO2-in air. 
 
3.3. Multicellular Spheroids Formation and Maintenance 
For spheroid generation, 6-well, 24-wells and 96-wells ULA flat-bottomed plates 
(Corning® Costar®) were inoculated with 1500 μL/well, 300 μL/well and 50 μL/well, 
respectively, of cell suspension at the optimized density of 250,000 cells/mL Spheroids culture 
medium consisted in DMEM supplemented with 10% FBS and 2% Growth Factor Reduced 
MatrigelTM (Corning®). Twenty-four hours for 6 and 24-wells plates and 2 h for 96-wells plates 
after inoculation, the volume of culture medium was doubled. Spheroids were incubated for 
up to 6 days with medium replacement every 3 days, in a humidified chamber at 37°C, 5% 
CO2. A scheme of spheroids formation is depicted in Fig. 5. 
Figure 5. Schematic representation of spheroids culture procedure. 
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3.4. Histology 
3.4.1. H&E 
Day-4 spheroids were resuspended in Tissue Tek® O.C.T.™ (Sakura®) for preparing 
cryosections of 5-7 μm. Slides were first stained with Harris's haematoxylin (Sigma-Aldrich®) 
for 20 min, followed by Eosin Y (Sigma-Aldrich®) staining for 2 min. Slides were then submitted 
to increasing concentrations of Ethanol and finally incubated in xylene (EMD Chemicals). 
Samples were mounted with Entellan® (Merck). Images were acquired on an Olympus CK30 
inverted microscope using Motic Images Version 2.0 software. 
3.4.2. Ki67 
Spheroid cryosections were fixed with pre-cooled acetone for 30 min at -20 °C, left 
drying and then, permeabilized with 0.08% Tween 20® for 2 min at room temperature (RT) 
and blocked for 30 min with 2% bovine serum albumin (BSA) in PBS. Incubation with primary 
antibody was performed overnight (ON) in a humidified chamber at 4°C. The primary antibody 
used was: Ki67 (Rabbit IgG, AB16667, Abcam®) diluted 1:100 In 1% BSA in PBS. The 
incubation with the secondary antibody goat anti-rabbit 594 (1:500) (Invitrogen™) was carried 
out for 1h at RT. Sections were mounted using ProLong gold antifade with DAPI (4',6-
diamidino-2-phenylindole, Invitrogen™) and observed on an inverted fluorescence 
microscope (Axiovert 200M, Carl Zeiss) coupled with a monochrome camera (AxioCam MNC, 
Carl Zeiss). Sample fluorescence was examined at excitation/emission wavelengths of 
590/617 nm (Alexa Fluor 594) and 358/461 (DAPI). Images were collected using AxioVision 
Rel. 4.7 software. 
 
3.5. MMPi Viability Assays 
The cytotoxicity of ARP-100, [15]pyN5 and [16]pyN5 was evaluated in MDA-MB-231 
cells in 2D and 3D culture conditions using CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega). In 2D cultures, 8x103 cells were seeded in 96-well plates and 
maintained for 24 h in DMEM supplemented with 10%FBS. Thereafter, cells were exposed to 
100 μL of ARP-100, [15]pyN5 and [16]pyN5 in final concentrations 100, 75, 50, 25, 10, 5, and 
1 µM, in serum free DMEM. After 24 h incubation, 20 μL MTS was added to the wells and left 
incubating for 1 h. The absorbance was recorded by spectrophotometry at 490 nm and 690 
nm (SPECTROstar Omega, BMG LABTECH). 
For 3D culture conditions, spheroids cultured in 96-welll ULA plates were used. Four-
day spheroids’ culture medium was replaced by 100 µL of DMEM with 1,25% FBS, 2% 
MatrigelTM and ARP-100, [15]pyN5 and [16]pyN5 (100, 75, 40, 10 and 1 µM). After 24 h, 
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spheroids were incubated 1 h with MTS. Spheroids were pelleted and the supernatant read 
by spectrophotometry at 490 nm and 690 nm. 
 The number of surviving cells was assessed by the determination of the difference of 
absorbance, A490 nm– A690 nm and cell viability was expressed as percentage to control. 
Experiments were performed in triplicates.  
 
3.6. Media Conditioning 
For medium conditioning under 2D conditions (CM2D), 1,500,000 cells were seeded 
in 75 cm2 T-flask for 24h reaching a 50% confluency. After washing twice with PBS, 15 mL 
serum-free DMEM was added to the cells. 3D medium conditioning (CM3D) was performed at 
day 4 of culture, in 6-well ULA plates. Spheroids were washed twice with serum-free DMEM, 
and medium substituted by 2 mL serum free DMEM supplemented with 2% MatrigelTM.  For 
both culture conditions, medium was conditioned for 24 h after which, it was harvested and 
concentrated about 100X in 10 kDa centrifugal concentrators (Millipore). Total protein was 
quantified by spectrophotometry (SPECTROstar Omega, BMG LABTECH) in a low volume 
microplate (Lvis plate, BMG LABTECH). Total protein concentration was determined through 
Lambert-Beer equation, with absorbance 280-340 nm and extinction coefficient of bovine 
serum albumin. 
 
3.7. Modified zymography assay 
To screen MMP-2 and 9 total gelatinase activity, a sodium dodecyl sulfate 
Polyacrylamide gel electrophoresis (SDS-PAGE), with the gel containing gelatin as substrate, 
was performed using the methodology described in [109] with modifications (Fig. 10). CM 
concentrated samples were resolved by electrophoresis under non-reducing conditions, in a 
10% Polyacrylamide containing 0.1% SDS and 0.1% (w/v) Gelatin. After electrophoresis, 
lanes were individualized and washed with 2.5% Triton X-100 in 3 steps of 20 min, to remove 
SDS. Lane gels were incubated for 24 h at 37 °C in, the Developing Buffer (50 mM Tris Base, 
200 mM NaCl, 5 μM ZnCl2, 5 mM CaCl2.2H2O and 0.02% NaN3) which restores the MMPs 
protease activity. ARP-100, [15]PyN5 and [16]pyN5 were tested by dissolving them in the 
Developing Buffer. Gels were revealed in 0,1% Coomassie Blue R-250 (National Diagnostics). 
MMP activity was detected as a clear band in the background of uniform staining. Band 
quantification was performed using ImageJ software (National Institutes of Health, USA). 
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3.8. Migration Assays 
3.8.1. Scratch Assay 
In vitro scratch assays were performed according to Liang et al. [110]. Briefly, 200,000 
MDA-MB-231 cells were seeded in 24-well plates. After 24 h incubation, medium was removed 
and a scratch performed with a 200-µL pipette tip, leaving a gap of approximately 0.7 mm in 
width. Cells were then rinsed twice with PBS and kept in serum-free medium containing 5-40 
µM of ARP-100, [15]pyN5 and [16]pyN5. The scratch was evaluated microscopically (Motic AE 
2000 inverted microscope), and four images of each scratch were recorded using Moticam 
2500 at defined time-points: 0, 5, and 10 and 24 h. Non-invaded distance was measured using 
Motic Images PLUS v2.0 software. Experiments were performed in triplicates. 
    
3.8.2. Radial Migration  
This assay was performed according to Vinci et al [104]. Flat-bottomed, 24-well plates 
(Sarstedt) were coated with 0.01 mg/mL with Poly-D-Lysine (Sigma-Aldrich®) in sterile water 
for 2 h at RT, followed by 1:30 diluted MatrigelTM coating for 30 min. Four-day spheroids were 
transferred to pre-coated plates and maintained in 500 μL of medium containing 10% FBS 
and 2% MatrigelTM and the compounds, ARP-100, [15]pyN5 and [16]pyN5 in concentrations 
ranging from 5-40 µM. Images were captured at 5, 10 and 24 h Motic AE 2000 inverted 
microscope. Effects of compounds were analyzed by measuring the distance between cells in 
the migration front and the perimeter of the spheroid. More than 10 spheroids per condition 
were analyzed, with 3 measures per spheroid.  
 
3.9. Statistical analysis 
Statistical analyses were carried by GraphPad Prism v6.0 software, (La Jolla, CA, 
USA). ANOVA with Tukey’s multiple comparison post-test was performed for 3 or 4 
independent assays. Anova repeated measures tool was used when there were values 
matching. Results are presented as means ±standard error of the mean (SEM), except where 
indicated. Statistical significance was represented as probability (p) value *<0.05, **<0.01 and 
***<0.001.   
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4. Results and Discussion 
 
4.1 Development of 3D Models of MDA-MB-231 
A suspension culture system using Ultra-Low Attachment (ULA) plates was developed 
and optimized in order to obtain MDA-MB-231 3D spheroids. ULA plates consist of plates 
coated with a hydrophilic and neutrally charged hydrogel that prevents cell adherence to the 
wells surface, therefore promoting cell aggregation. For this purpose, different culture 
parameters such as inoculum concentration, FBS concentration and ECM supplementation 
were evaluated. MDA-MB-231 cells were cultured in 24-well plates for 6 days in a batch mode 
consisting of culture medium replacement every 3 days (Fig. 5).  
Medium supplementation with both 10% and 20% FBS, did allow formation of cell 
aggregates. However, these aggregates were easily disrupted and were heterogeneous in 
size and morphology (Fig. 6 A). To obtain more compact spheroids of MDA-MB-231 cell line, 
previous reports [111] recommend the addition of a reconstituted basement membrane. 
MatrigelTM [112], which is a commercially available basement membrane preparation extracted 
from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, rich in ECM proteins (e.g. laminin, 
collagen IV and heparin sulfate proteoglycans), was therefore added to the 10% FBS cultures 
at the inoculation step. Indeed, as shown in Fig. 6 B, 2% MatrigelTM allowed the formation of 
more compact and homogenous spheroids. Consequently, the 10% FBS condition with 2% 
MatrigelTM was further adopted. 
According to previous reports [96, 111] cell densities ranging from 125,000 to 315,000 
cell/mL were initially tested (Fig. 6 B). Twenty-four hours were given for cells aggregation, 
after which media volume was doubled. Measurements of spheroids were based on phase-
contrast images up to day 6 of culture, yielding a size-distribution plot (Fig. 6 C).  
With the higher inoculums (315,000 cells/mL), larger but more heterogeneous 
spheroids were obtained. As for the inoculum concentrations of 125,000 and 250,000 cells/mL, 
homogeneous spheroids were observed from day 4 onwards. However, in order to obtain a 
conditioning medium volume per cell in 3D cultures as in the two-dimensional system (further 
explored in Chapter 4.3.1.), the inoculum of 125,000 cells/mL was considered inadequate as 
it would require a very low cell confluence for medium conditioning in the 2D model. Therefore, 
for MDA-MB-231 spheroids development, the condition with cell density of 250,000 cells/mL 
in media supplemented with 10% FBS and 2% MatrigelTM was adopted and further 
characterized up to day 4. 
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Figure 6. Optimization of MDA-MB-231 spheroids development conditions. A) Contrast phase 
pictures of aggregates formed without MatrigelTM (MG), from inoculum 315,000 cells/mL, at day 4 
and 6 of culture (magnification 4X, scale bars=200 μm; magnification 10X, scale bar=100 μm). B) 
Contrast phase pictures of spheroids with 2% MatrigelTM from inoculums 125,000; 250,000 and 
315,000 cells/mL at day 4 and 6 of culture (magnification 4X, scale bars=200 μm) Pictures taken with 
inverted microscope. C) Distribution plot for spheroids diameters (µm) at day 4 and 6 of culture of 
cells inoculated at 125,000; 250,000 and 315,000 cells/mL. 
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Figure 7. Characterization of MDA-MB-231 spheroids (inoculum 250,000 cell/mL in 10% FBS 
and 2% MatrigelTM supplemented media). A) Representative phase contrast images of the 
spheroids from day 1 to day 4. Pictures taken with inverted microscope (scale bars=100 μm for 
magnification 4X, and 10X); B) Spheroids diameters (µm) over culture time represented as mean ± 
SD). C) Percentage of MTS and total protein of days 2 and 4 relative to day 1 of culture. (mean ± 
SEM, n=2-3). D) Cryosections stained with Hematoxylin & Eosin. Scale bar=100 μm. E) Cryosection 
immunolabeled with Ki-67(pink) and Dapi (blue). Major Figure scale bar= 100 μm. Minor Figure scale 
bar=20 μm. 
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Phase contrast microscopy shows that at day 1, MDA-MB-231 cells inoculated at a cell 
density of 250.000 cells/mL, form small aggregates of approximately 90 µm diameter (Fig. 7 
A and B). These aggregates further gathered, forming spheroids with increasing sizes and 
compactness over culture time. On average, spheroid diameters were 147 ± 64 µm (mean ± 
SD) at day 2 and 191 ± 95 µm (mean ± SD) at day 4 of culture (Fig. 7 B). From day 4 onwards 
the spheroids diameter was maintained (data not shown). To further monitor the morphology 
of the spheroids, histological analysis of spheroid cryosections were performed at day 4. H&E 
staining of sections revealed that spheroids were solid with cells homogeneously distributed 
and embedded in extracellular matrix presenting no evidence of necrotic cores (Fig. 7 D). 
Immunolabeling with the proliferative marker Ki-67 (Fig. 7 E) shows 15% proliferating cells, 
including cells within the spheroid. This proliferation percentage is in agreement with the 
observed 1.2-fold increase in total protein (Fig. 7 C). These results together with the MTS 
assay data (Fig. 7 C), show reduced proliferation in 3D cultures when compared with 
monolayer models, a pattern which has been broadly reported for many cancer cell lines 
including MDA-MB-231 [111, 113, 114]. Several factors, which induce this change in 
proliferation have been described, such as hypoxia and nutrients hindered diffusion, ECM 
elements and their stiffness [114–116]. Proliferation marker Ki-67 has been used as a 
prognostic marker for breast cancer, with most in vivo tumors having under 50% Ki-67+cells. 
This contrasts with a very different percentage,100% Ki-67+cells, reported in  MDA-MB-231 
monolayer [117].  
Obtaining a realistic proliferation is vital for the assessment of potential 
chemotherapeutic agents, and also important for better understanding of breast cancer cell 
heterogeneity and classification. MDA-MB-231 cell line has been described as a highly 
proliferative triple-negative cells belonging to Basal-like tumors’ type. Recently, a new subtype 
of breast tumors was identified, claudin-low [118]. These subtype is characterized for low or 
no expression of epithelial cell-cell adhesion molecules E-cadherin and Claudin-3,4 and 7 and 
high expression of EMT markers such as Vimentin and EMT transcription factors (e.g. Twist 
and SnaiI). The claudin-low subtype is also described to have a stemness signature by having 
high CD44/CD24 and CD49f/Epithelial cell adhesion molecule (EpCAM) ratios, and by having 
a low percentage of Ki-67+ cells, indicating lower proliferation when compared to other 
subtypes, such as Basal-like. A screening of several breast cancer cell lines identified nine 
cell lines, including MDA-MB-231, with the same expression profiles as claudin-low subtypes 
[119]. The main difference between cell lines and the primary tumor identified as claudin-low 
was the proliferation gene cluster, which could be a result of the selection imposed on cell 
lines or of the standard in vitro conditions. Thus, 3D models may give further insight about 
these cell lines by being able to reveal information that has been hiding under non-
physiological culture conditions [120]. Moreover, MDA-MB-231 not expressing E-cadherin 
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could explain why these cells do not form spheroids spontaneously as they have their cell-
cell-adhesion ability hampered. Hence, these cells require the addition of extrinsic ECM to 
form compact spheroids as they only tightly aggregate through integrin-β1 (cell-matrix 
interactions molecule) [99].  
 
4.2. Cell Viability Assays   
In order to rule out direct cytotoxic effects that could somehow conflict with migration 
assays, dose-response curves were performed to determine concentrations of the compounds 
[15]pyN5, [16]pyN5 and ARP-100,  with no, or limited, effect on cells viability. The cytotoxicity 
activity of these compounds in both 2D and 3D models of MDA-MB-231 was assessed through 
MTS assay that detects viable and metabolic active cells. Since some of the cellular assays 
are performed in serum free conditions (e.g. scratch-assay), the cytotoxicity assays were also 
performed in serum-free conditions. Following the concentrations of ARP-100  used in 
literature [46,69], concentrations ranging 1-100 μM were chosen (Fig. 8). As for [15]pyN5, 
[16]pyN5 the same range of concentrations was adopted. 
As depicted in Fig. 8 A and B, both pyridine containing macrocycles (py-macrocycles) 
induced a slight decrease on cell viability in 2D cultures at concentrations higher than 10 and 
25 μM for [15]pyN5 and [16]pyN5, respectively. Up to 75 μM, viability was higher than 74%, 
decreasing to ~60% at 100 μM concentrations for both [15]pyN5 and [16]pyN5. The cytotoxicity 
profile observed in spheroids cultures was very similar between both py-macrocycles, with 
viability values never below 80% (Fig. 8 A and B). 
Concentrations of ARP-100 up to 25 μM, showed no cytotoxicity in monolayers (Fig. 8 
C). At a concentration of 50 μM, cell viability was 75% and decreased in a concentration 
dependent manner, attaining the value of 44% at 100 μM of ARP-100. In spheroid cultures, 
ARP-100 did not exhibit the same dose-response curve. Cell viability was never lower than 
78%. In particular, for the ARP-100 concentrations of 75 and 100 µM, significantly higher 
(p<0.05 and p<0.01, respectively) cell viabilities were obtained in 3D cultures when compared 
to monolayer. These results suggest that the 3D model is more resistant to ARP-100 than the 
monolayer one. The toxicity mechanism for ARP-100 is not known and it is beyond our scope 
to explain the phenomenon in this specific case. Nevertheless, higher resistance of 3D models 
has been broadly reported [104, 108, 121], with the exception of some cell lines and drugs. 
As an example, it has been shown that in HT080 in 3D collagen fibers [121] and MCF-7 
spheroids [94], proliferation and viability, respectively, were less affected by doxorubicin than 
monolayer cultures. The overall higher resistance of the 3D models has been related to the 
quiescence as aforementioned, ECM-mediated signaling pathways [122, 123] (e.g. apoptotic 
pathways) and even hypoxia-mediated P-glycoprotein up-expression [124]. Furthermore, 
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similarly to the gradient of nutrients and oxygen, drug penetration is also somewhat hindered 
in spheroids, once again mimicking the hindered diffusion in solid tumor [125, 126]. 
Following the viability assay studies, compounds’ concentrations ranging 5-40 µM 
were adopted, in order to have a cell viability above 70 %.  
  
  
Figure 8. Effect of A) [15]pyN5, B) [16]pyN5 and C) ARP-100 on MDA-MB-231 cell viability on 
2D and 3D models, evaluated through the MTS assay. Results are expressed in percentage 
(mean± SEM, n=3;4) to respective controls, non-treated condition for [15]pyN5 and [16]pyN5 and 
0.25% DMSO for ARP-100. Statistical significance is expressed relatively to respective controls as 
*p<0.05, **p<0.01, ***p<0.001. 
 
 
4.3.1. Optimization of Zymography technique and Media conditioning 
A zymography technique, in which gelatin is used as substrate for MMP-2/9 and 
pro-MMP-2/9, was implemented to screen both enzyme activities. The first step is equivalent 
to a common SDS-PAGE, except for that it must be performed under non-reducing conditions. 
After electrophoresis, the gel is washed to remove SDS and then incubated with a buffer 
A B 
C 
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containing MMP cofactors Ca2+ and Zn2+, at a physiologic pH and salt concentration. In this 
last step, the MMPs contained in the gel degrade the gelatin, leaving a clear band after staining 
with Coomassie®. To confirm that the bands observed in the zymography gels were of MMP 
nature, gels developed in the presence or absence of EDTA (7.8 mM) were also compared. 
Indeed, EDTA inhibited the clear bands corresponding to the MMP-2 and MMP-9 molecular 
weights (Fig. 9 A). 
Prior to medium conditioning, tests were performed to determine the optimal 
conditioning time (24, 48, 72 and 96 h) (Fig. 9 B), CM concentration and quantity of total 
protein of CM to be loaded in the gels. Moreover, culture volume was adjusted accordingly, in 
order to obtain a conditioning volume per cell in 3D cultures as in the two-dimensional system. 
The adopted ratio was of ~200,000 cells/mL Conditioning periods longer than 24 hours in 
serum free conditions resulted in increased cell death (30% cell death with 0.25% DMSO in a 
48 h incubation) (data not shown), therefore it was established a conditioning incubation period 
not exceeding 24 hours. Furthermore, a volume concentration of ~100 X was adopted to 
ensure a sufficient gelatinase concentration.  
Following this optimization, CM2D and CM3D were analyzed by zymography, showing 
a differential MMP-2 and 9 secretion (Fig. 9 C and D). Whereas in CM2D, there was more 
MMP-2 activity than MMP-9, in CM3D the contrary was observed. Therefore, culturing cells 
as spheroids induce different gelatinase secretion. The more in vivo-like cell-cell and cell-ECM 
interactions might have a role in this secretome change, as cell adhesion molecules such as 
integrins have been described to modulate MMPs expression [127, 128].  
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4.3.2. Modified Zymography Assays for Gelatinolytic activity assessment 
The objective of this work was to access possible direct MMP inhibitors. Since SDS 
has been indicated as a disrupting agent of TIMPs-MMP binding, the gelatinolytic activity that 
would be observed in the presence of SDS would be independent of the TIMP content [129]. 
Gelatinase inhibitors, similarly to TIMPs, might be released from the proteins in the SDS-
PAGE gel [79]. Therefore, modifications were made to the zymography technique, as 
illustrated in Fig. 10. This technique differs from classical zymography by adding the 
compounds to the developing buffer incubation step, instead of incubating cells and their 
conditioned medium with the compounds. Therefore, changes in bands intensity directly 
reveal the influence that the compounds have in the MMP-2/9 gelatinolytic activity.  
 
Figure 9. Gelatin Zymography Optimization. A) Zymography gels incubated with and without 7.8 
mM EDTA in the developing buffer. B) Medium conditioning duration (24-96 h) correlation with pro-
MMP-9 secretion. C)  Zymography gels with CM2D and CM3D.D) CM2D and CM3D (n=5) MMP-2 
and MMP-9 gelatinolytic activity (arbitrary units of ImageJ software). Values are represented as mean 
± SD, and statistical significance as *p<0.05 and ** p<0.01. 
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Figure 10. Schematic representation of the modified zymography technique adopted. 
 
To analyze if the compounds [15]pyN5, [16]pyN5 and ARP-100 were able to inhibit 
MMP-2 and MMP-9 gelatinolytic activity in CM2D and CM3D, the modified zymography assay 
was performed (Fig. 11).  
The method was shown to be reproducible, ie, gels (n=5) loaded with CM3D and 
treated with 5 and 10 μM of ARP-100, showed MMP-9/MMP-2 inhibition of 45±12%/58±12% 
(5 µM) and 56±14%/79±12% (10 µM), respectively (mean ± SD). Ten µM of ARP-100 tested 
in CM2D (Fig. 11 B) also inhibited more MMP-2 activity than MMMP-9. Hence, this differential 
inhibition may reflect the ARP-100 specificity for MMP-2. As seen in Fig. 11 A, for ARP-100 a 
~100% Gelatinolytic activity (MMP2 and 9) inhibition was only observed at 40 µM. 
 
 
2. Conditioned media collection and concentration of volume ~100 X.  
1. Serum free media conditioned for 24-hours. 
3. 50 µg of total protein is loaded per lane in a SDS-PAGE gel 
copolymerized with gelatin. Proteins are separated by size. 
6. Twenty-four hours incubation at 37 ⁰C with developing buffer in the 
presence of control vehicle or MMP inhibitors.  
7. Gel staining with Coomassie Brilliant Blue. Bands densitometry 
measured using ImageJ. 
4. Lanes are individually cut. 
5. One hour washing step with Triton X-100 to remove SDS.  
Control MMPi 
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Figure 11. Effect of [16]pyN5, [15]pyN5 and ARP-100  on MMP2 and MMP-9 gelatinolytic activity. 
A) CM3D zymography gels incubated with 5-40 µM of [16]pyN5, [15]pyN5 and ARP-100 in the 
developing buffer. B) CM2D zymography gels incubated with 10 µM of ARP-100 in the developing 
buffer. C) Gelatinolytic activity of MMP-2 and 9 from CM3D in the presence of [16]pyN5, [15]pyN5 and 
ARP-100, quantified through ImageJ software. 
 
 
The compounds [15]pyN5 and [16]pyN5 had the same inhibition profile, consisting in 100% 
inhibition for concentrations above 7.5 μM in CM3D (Fig. 11 A) and 10 μM in CM2D (data not 
shown), whereas no inhibition was obtained at 5 μM. The values of pZn2+ vs the concentration 
of [15]pyN5 and [16]pyN5, (Fig. 12) were simulated through Hyss program [130], using the 
compounds stability constants for Zn2+ and species distribution. The equivalence point 
obtained in the simulation coincided with the steep obtained in the zymography assay, pointing 
towards a correlation between the chelation of free Zn2+ and the inhibition of gelatinases by 
the compounds. 
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Figure 12. Values of pZn2+ (-log[Zn2+]), calculated using [130], for an aqueous solution of pH 7.4 
containing Zn2+(5 μM) and [16]pyN5 and [15]pyN5 (0.1-40 µM). 
 
4.4. Migration Assays  
In order to evaluate cell migration scratch and radial [96] assays were applied in 2D 
and 3D cultures, respectively. In monolayer cultures, scratch assays were performed in serum-
free conditions, so that the closure of the scratch resulted for cells migration and not as a result 
of proliferation. In fact, significant effects for both py-macrocyles, when comparing to non-
treated control condition, were observed for concentrations as low as 5 μM, with [16]pyN5 and 
[15]pyN5 decreasing cell migration 38 ± 2% and 21 ± 4%, respectively (Fig. 13). Py-macrocyles 
hampered migration also at higher concentrations, although no significant changes in the 
migration distance between the different concentrations tested, were observed. As for ARP-
100, when compared to its control of 0.25% DMSO condition, although showing a slight 
inhibitor tendency, it was not found to be significant at any concentration tested. In fact, other 
mechanisms, besides MMP-2 and 9 inhibition, may be involved in these py-macrocycles 
hampering effect on monolayer cellular migration. Since MMP-2 and 9 inhibition is related to 
zinc chelation and MMPs have a highly conserved zinc-dependent catalytic site, [15]pyN5 and 
[16]pyN5 probably also inhibit other MMPs. Still, if py-macrocycles mechanism is based on 
overall MMPs inhibition, herein it is shown that although this inhibition affects cell migration on 
2D culture conditions, it is not crucial. In fact, the essentiality of MMPs for invasion has been 
broadly describe, but its role in migration per se is still being disclosed.  
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Specifically in scratch assays, inhibition of MMPs through gene silencing [131, 132] 
antibody neutralization, [133] and pharmacological inhibitors such as batimastat [132] have in 
fact shown to have a deleterious effect on cell migration, although never ablating it completely. 
Since in scratch assay cell-matrix adhesions are not present, MMPs role in this motility is most 
probably by cleaving cell-attachment receptors directly, modulating cells adhesion during 
 
Figure 13. Scratch Assay with [15]pyN5, [16]pyN5 and ARP-100. A) Cells migration represented 
as percentage (mean±SEM) relative to controls (non-treated condition for [15]pyN5 and [16]pyN5 and 
0.25% DMSO for ARP-100), after 24 hours. B) Representative images of scratch assays at 0 and 24 
hours with 5 μΜ of compounds and respective controls. Magnification 4 X, scale bar=200 μm. 
Statistical significance is represented as * p<0.05, ** p<0.01, *** p<0.001. 
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migration [134] and triggering signaling pathways involved in migration and angiogenesis [40]. 
Indeed MT-MMP1 was shown to shed CD44 [135], MMP-9 to cleave CD44 and integrin αMβ2 
[136] and MMP-2 to cleave integrin αVβ3 [46], further promoting migration. Besides it is 
noteworthy that MMPs function extend beyond proteolytic functions, as their hemopexin 
domains have been shown to have important roles in migration [137, 138]. Dufour et al [139] 
showed that Gelatinases-induced migration did not depend on their proteolytic functions. 
MMP-9-induced migration shown to be dependent of its hinge and hemopexin domains and 
not to alter adhesion ability.  
In the radial assays, 10% FBS supplemented medium was adopted, since serum-free 
medium disabled cells migration ability (data not shown). As depicted in Fig. 14, py-
macrocycles showed a trend of decreased migration with increasing concentrations, being 
significant for 20 μM [16]pyN5 which decreased cell migration 20±4%. ARP-100 only resulted 
in a significant cell migration decrease of 23±3% relative to control (0.25% DMSO) at 40 μM.  
The results herein obtained in terms of MDA-MB-231 cellular migration under 3D and 
2D conditions, suggest that spheroids are less susceptible than 2D models to the tested 
compounds. Several reasons may justify the observed effects. Although migrated distances 
in both 2D and 3D controls were similar (~260 μm), scratch assay was performed in serum 
free conditions while radial migration was performed with 10% FBS. Compounds 
bioavailability might be affected by FBS. ECM such as MatrigelTM, which was present in the 
3D culture both embedded in the spheroids and in the coating, has also been indicated to 
influence migration susceptibleness to compounds. Millerot-Serrurot et al. [140] described that 
HT1080 cells in 3D collagen I matrix had no significant migration inhibition, at the same 
doxorubicin concentrations that induced 70% inhibition in 2D models. Moreover, the GM6001 
broad MMPi abrogates ovarian cancer cell lines monolayers and spheroids cell migration in 
collagen I matrix but not in MatrigelTM, showing the relevance of ECM elements for migration 
and invasion [105]. Furthermore, as mentioned in the Chapter 4.2, similarly to in vivo, the 
compounds might not diffuse completely to the more central zone of the spheroid, affecting 
just the periphery.  
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Figure 14. Radial migration assays with [15]pyN5, [16]pyN5 and ARP-100. A) Cells migration 
represented as percentage (mean±SEM) relative to controls (non-treated condition for [15]pyN5 and 
[16]pyN5 and 0.25% DMSO for ARP-100), after 24 hours. B) Representative images of Radial 
Migration at 24 hours with compounds and respective controls. Magnification 4 X, scale bar=200 μm. 
Statistical significance is represented in * p<0.05 when compared to respective controls. 
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5. Conclusion 
 
In this work, 3D models of human breast cancer cells (MDA-MB-231 cells) were 
successfully implemented and characterized. These models present important differences 
relatively to monolayers, in terms of ECM presence and cell organization inducing different 
proliferation profile and gelatinases activity. These differences may justify the different 
susceptibility of the model to the compounds herein tested as possible anti-migratory agents. 
The two macrocyclic compounds containing pyridine reduced cell migration in 2D 
models, and [16]pyN5 in 3D models, probably involving MMP-2 and 9, or even overall MMPs 
proteolytic activity inhibition. To further clarify both, the mechanism of these compounds and 
the roles of MMPs, the next step of this study will be to perform invasion assays and eventually 
analyze if the py-macrocycles induce changes in EMT related pathways such as PI3K. 
If [15]pyN5 and [16]pyN5 prove to be efficient inhibitors of other metastization hallmarks, 
they might be a good starting point for new molecules design. Molecular Docking analysis 
would have to be performed to understand the interaction of these compounds with the MMPs, 
and consequently their inhibition mechanism. Although these py-macrocycles zinc binding 
ability was enough for 100% inhibition of gelatinases activity, specificity for zinc over other 
essential divalent cations is highly desirable [31]. Moreover, although specificity of MMPs over 
other proteins is much desired, ARP-100 not surpassing the py-macrocycles effects, raises 
doubts about the value of selectivity within the MMPs group.  
If 3D models keep their relative insensibility to compounds in invasion assays, the 
results should not be perceived with less interest.  As mentioned in the introduction, 3D models 
came to bridge the more complex models with monolayers to prevent drug attrition. Meaning 
that compounds that usually fail in latter phases of drug development, might fail earlier by 
testing them in these 3D models. And so the model might be in fact fulfilling its original scope.  
Besides, the 3D models have a great potential of giving further insights on tumors progression 
and hence better strategies to target them. 
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